. 2022 Sep 14;13:959658. doi: 10.3389/fimmu.2022.959658

Table 2.

Acute GVHD characteristics and response following autologous MSC infusion.

Study ID	Dose level; # doses	Time from GVHD dx (days)	Max grade; stage¹	Treatment on day 1	Other treatments	Timepoint	Grade	Stage	Overall response	Steroid dose (mg/kg)
EPIC2014-01²	1; 1	129	II; 3/0/0/0	Steroid, FK, ECP	ATG	D1	II	2/0/0/0	CR	0.7→0³
						D8	I	1/0/0/0
						D15	I	1/0/0/0
						D29	I	1/0/0/0
						D36	I	1/0/0/0
						3 months	II	3/0/0/0
						6 months	0	0/0/0/0
EPIC2014-05	1; 1	77	IV; 0/1/4/0	Steroid, FK, ruxolitinib, ECP	ATG, MMF, infliximab	D1	IV	0/1/4/0	MR	0.9→0.6
						D8	IV	0/1/4/0
						D15	II	0/0/1/0
						D29	IV	0/0/4/0
						D36	I	0/1/0/0
						D42	IV	0/1/4/0
						2 months	I	0/1/0/0
						3 months	III	0/0/0/3
EPIC2014-06⁴	1; 1	146	IV; 0/1/4/0	Steroid, FK	Sirolimus, MMF, ECP	D1	IV	0/0/4/0	NR	1.1→0.7
						D8	IV	0/1/4/0
						D15	IV	0/0/4/0
						D29	IV	0/0/4/0
						D36	IV	0/1/4/0
EPIC2014-15	3; 4	122	III; 0/0/2/0	Steroid, FK	Remicade, Jakafi	D1	II	0/0/1/0	PR	1.0→0
						D8	II	0/0/1/0
						D15	II	0/0/1/0
						D29	II	0/0/1/0
						D36	III	0/0/2/0
						2 months	III	0/0/2/0
						3 months	III	0/0/2/0
						6 months	II	0/0/1/0
						12 months	II	0/0/1/0

GVHD, graft-versus-host disease; MSC, mesenchymal stromal cells; Max, maximum; FK, tacrolimus; ECP, extracorporeal photopheresis; ATG, anti-thymocyte globulin; MMF, mycophenolate mofetil; CR, complete response; NR, no response; PR, partial response; UGI, upper gastrointestinal; LGI, lower GI.

(1)Stage reported as skin/UGI/LGI/liver.

(2)Chronic GVHD diagnosed on 2/24/2015. Skin GVHD developed chronic features during the study.

(3)Steroids weaned off within a few days of first MSC infusion.

(4)Overlap GVHD with acute phenotype.